236 related articles for article (PubMed ID: 31484564)
1. Haemophilia A: health and economic burden of a rare disease in Portugal.
Café A; Carvalho M; Crato M; Faria M; Kjollerstrom P; Oliveira C; Pinto PR; Salvado R; Dos Santos AA; Silva C
Orphanet J Rare Dis; 2019 Sep; 14(1):211. PubMed ID: 31484564
[TBL] [Abstract][Full Text] [Related]
2. The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease.
Henrard S; Devleesschauwer B; Beutels P; Callens M; De Smet F; Hermans C; Speybroeck N
Orphanet J Rare Dis; 2014 Mar; 9():39. PubMed ID: 24655371
[TBL] [Abstract][Full Text] [Related]
3. Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.
Nerich V; Tissot E; Faradji A; Demesmay K; Bertrand MA; Lorenzini JL; Briquel ME; Pouzol P; Woronoff-Lemsi MC
Pharm World Sci; 2008 Jun; 30(3):287-92. PubMed ID: 18085428
[TBL] [Abstract][Full Text] [Related]
4. Social/economic costs and quality of life in patients with haemophilia in Europe.
Cavazza M; Kodra Y; Armeni P; De Santis M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Gulácsi L; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():53-65. PubMed ID: 27048374
[TBL] [Abstract][Full Text] [Related]
5. The cost of severe haemophilia in Europe: the CHESS study.
O'Hara J; Hughes D; Camp C; Burke T; Carroll L; Diego DG
Orphanet J Rare Dis; 2017 May; 12(1):106. PubMed ID: 28569181
[TBL] [Abstract][Full Text] [Related]
6. Costs and utilization of treatment in patients with hemophilia.
Rocha P; Carvalho M; Lopes M; Araújo F
BMC Health Serv Res; 2015 Oct; 15():484. PubMed ID: 26502954
[TBL] [Abstract][Full Text] [Related]
7. The burden of disease and the cost of illness attributable to child maltreatment in Japan: long-term health consequences largely matter.
Mo X; Gai RT; Tachibana Y; Bolt T; Takahashi Y; Nakayama T
BMC Public Health; 2020 Aug; 20(1):1296. PubMed ID: 32854682
[TBL] [Abstract][Full Text] [Related]
8. Unmeasured costs of haemophilia: the economic burden on families with children with haemophilia.
Price VE; Hawes SA; Bouchard A; Vaughan A; Jarock C; Kuhle S
Haemophilia; 2015 Jul; 21(4):e294-9. PubMed ID: 25955276
[TBL] [Abstract][Full Text] [Related]
9. Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal.
Magro F; Portela F; Lago P; Chagas C; Moreira F; Pereira F; Rodrigues B; Pedrosa H; Correia L
GE Port J Gastroenterol; 2023 Aug; 30(4):283-292. PubMed ID: 37767302
[TBL] [Abstract][Full Text] [Related]
10. Healthcare resource utilization among haemophilia A patients in the United States.
Valentino LA; Pipe SW; Tarantino MD; Ye X; Xiong Y; Luo MP
Haemophilia; 2012 May; 18(3):332-8. PubMed ID: 22044662
[TBL] [Abstract][Full Text] [Related]
11. Treatment-resistant depression and major depression with suicide risk-The cost of illness and burden of disease.
Sousa RD; Gouveia M; Nunes da Silva C; Rodrigues AM; Cardoso G; Antunes AF; Canhao H; de Almeida JMC
Front Public Health; 2022; 10():898491. PubMed ID: 36033799
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study.
Rodriguez-Santana I; DasMahapatra P; Burke T; Hakimi Z; Bartelt-Hofer J; Nazir J; O'Hara J
Orphanet J Rare Dis; 2022 Apr; 17(1):150. PubMed ID: 35379284
[TBL] [Abstract][Full Text] [Related]
13. Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness.
Neves M; Trigo F; Rui B; João C; Lúcio P; Mariana N; Mendes J; Pedrosa H; Geraldes C
Pharmacoeconomics; 2021 May; 39(5):579-587. PubMed ID: 33517511
[TBL] [Abstract][Full Text] [Related]
14. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS).
Globe DR; Curtis RG; Koerper MA;
Haemophilia; 2004 Mar; 10 Suppl 1():63-70. PubMed ID: 14987251
[TBL] [Abstract][Full Text] [Related]
15. Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHESS II study.
Rodriguez-Santana I; DasMahapatra P; Burke T; Hakimi Z; Bartelt-Hofer J; Nazir J; O'Hara J
Orphanet J Rare Dis; 2022 Apr; 17(1):148. PubMed ID: 35379282
[TBL] [Abstract][Full Text] [Related]
16. Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.
Thorat T; Neumann PJ; Chambers JD
J Manag Care Spec Pharm; 2018 Jul; 24(7):632-642. PubMed ID: 29952709
[TBL] [Abstract][Full Text] [Related]
17. The Jamaican Haemophilia Registry: Describing the burden of disease.
Wharfe G; Buchner-Daley L; Gibson T; Hilliard P; Usuba K; Abad A; Boma-Fischer L; Bouskill V; Floros G; Lillicrap D; Lowe Y; Lowe D; Palmer-Mitchell N; Rand ML; Teitel J; Tuttle A; Watson A; White R; Young NL; Blanchette VS
Haemophilia; 2018 Jul; 24(4):e179-e186. PubMed ID: 29855125
[TBL] [Abstract][Full Text] [Related]
18. The economic impact of factor VIII inhibitors in patients with haemophilia.
Bohn RL; Aledort LM; Putnam KG; Ewenstein BM; Mogun H; Avorn J
Haemophilia; 2004 Jan; 10(1):63-8. PubMed ID: 14962222
[TBL] [Abstract][Full Text] [Related]
19. Health economics in haemophilia: a review from the clinician's perspective.
Escobar MA
Haemophilia; 2010 May; 16 Suppl 3():29-34. PubMed ID: 20586799
[TBL] [Abstract][Full Text] [Related]
20. The societal burden of haemophilia A. II - The cost of moderate and severe haemophilia A in Australia.
Brown LJ; La HA; Li J; Brunner M; Snoke M; Kerr AM
Haemophilia; 2020 Aug; 26 Suppl 5():11-20. PubMed ID: 32935398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
